公开(公告)号：US20240261413A1

公开(公告)日：2024-08-08

申请号：US18628449

申请日：2024-04-05

申请人： The Regents of the University of Minnesota

发明人： James C. Cloyd

IPC分类号： A61K47/40 ,  A61K9/00 ,  A61K31/357 ,  A61K31/724

CPC分类号： A61K47/40 ,  A61K9/0019 ,  A61K31/357 ,  A61K31/724

摘要： The present invention is directed to compositions comprising topiramate and a sulfoalkyl ether cyclodextrin, and methods of making and using the same.

公开(公告)号：US20240245709A1

公开(公告)日：2024-07-25

申请号：US18625718

申请日：2024-04-03

申请人： MARINUS PHARMACEUTICALS, INC.

发明人： Henrikas VAITKEVICIUS ,  Maciej Gasior ,  Joseph Hulihan

IPC分类号： A61K31/57 ,  A61K9/00 ,  A61K31/724

CPC分类号： A61K31/57 ,  A61K9/0019 ,  A61K31/724

摘要： This invention relates to methods for treating established status epilepticus (ESE) by administering to the subject in need thereof an intravenous bolus of ganaxolone and a continuous intravenous infusion of a neurosteroid. The method provides ESE suppression and continued suppression of ESE.

公开(公告)号：US20240238327A1

公开(公告)日：2024-07-18

申请号：US17915943

申请日：2022-02-28

申请人： RENATUS INC.

发明人： Hee Gon KIM

IPC分类号： A61K31/724 ,  A61K31/195 ,  A61K38/26 ,  A61P3/06

CPC分类号： A61K31/724 ,  A61K31/195 ,  A61K38/26 ,  A61P3/06

摘要： Provided are: a pharmaceutical composition including a gamma-cyclodextrin-based polymer, for prevention and treatment of diseases related to cholesterol metabolism dysregulation; and use thereof. The pharmaceutical composition including a gamma-cyclodextrin polymer for prevention or treatment of diseases related to cholesterol metabolism dysregulation, according to an embodiment, by including the gamma-cyclodextrin-based polymer, may minimize extraction of plasma membrane cholesterol and thus not cause cytotoxicity and hemolytic activity, thereby facilitating intracellular metabolism and excretion of cholesterol, and effectively suppressing the secretion of IL-1β, MCP-1, and TNF-α cytokines, thereby exhibiting an excellent anti-inflammatory effect.

公开(公告)号：US20240189341A1

公开(公告)日：2024-06-13

申请号：US18011194

申请日：2022-06-21

申请人： REMEGEN CO., LTD.

发明人： Xinling ZHANG ,  Wenting LUO ,  Yue WANG ,  Jie ZHOU ,  Qilin YIN ,  Changjiang HUANG ,  MARIE M. ZHU

IPC分类号： A61K31/724 ,  A61K47/68 ,  A61P35/00 ,  C07K16/32

CPC分类号： A61K31/724 ,  A61K47/6877 ,  A61P35/00 ,  C07K16/32 ,  C07K2317/24

摘要： The present disclosure provides a pharmaceutical combination and use thereof. By using an effective amount of methyl-β-cyclodextrin as a preparation component or a combined auxiliary drug, the efficacy of ADC can be significantly improved, so that some of the ADC drugs with safety issues caused by excessive dosage can be developed. Moreover, due to the reduction in the dosage of ADC drugs, the cost of production and the cost of treatment for patients have also been greatly reduced, thereby being beneficial.

公开(公告)号：US20240165125A1

公开(公告)日：2024-05-23

申请号：US18336419

申请日：2023-06-16

申请人： Lundbeck Pharmaceuticals LLC

发明人： James CLOYD ,  Angela BIRNBAUM ,  Ilo LEPPIK ,  Stephen D. COLLINS

IPC分类号： A61K31/55 ,  A61K9/00 ,  A61K31/724 ,  A61K47/40 ,  A61K47/69 ,  B82Y5/00 ,  C08B37/16

CPC分类号： A61K31/55 ,  A61K9/0019 ,  A61K31/724 ,  A61K47/40 ,  A61K47/6951 ,  B82Y5/00 ,  C08B37/0012 ,  C08B37/0015

摘要： The present invention is directed to a carbamazepine-cyclodextrin inclusion complex useful for the parenteral administration of carbamazepine. The carbamazepine-cyclodextrin inclusion complex is prepared by the admixture of a modified cyclodextrin and carbamazepine in a physiologically acceptable fluid. Modified cyclodextrins include 2-hydroxypropyl-beta-cyclodextrin and sulfoalkyl cyclodextrins. More particularly, the sulfoalkyl cyclodextrins are those described and disclosed in U.S. Pat. Nos. 5,134,127 and 5,376,645. A physiologically acceptable fluid includes sterile isotonic water, Ringer's lactate, D5W (5% dextrose in water), physiological saline, and similar fluids suitable for parenteral administration.

公开(公告)号：US11969470B2

公开(公告)日：2024-04-30

申请号：US17384616

申请日：2021-07-23

申请人： Regents of the University of Minnesota

发明人： James C. Cloyd

IPC分类号： A61K47/40 ,  A61K9/00 ,  A61K31/357 ,  A61K31/724

CPC分类号： A61K47/40 ,  A61K9/0019 ,  A61K31/357 ,  A61K31/724 ,  A61K31/357 ,  A61K2300/00 ,  A61K31/724 ,  A61K2300/00

摘要： The present invention is directed to compositions comprising topiramate and a sulfoalkyl ether cyclodextrin, and methods of making and using the same.

公开(公告)号：US11938144B2

公开(公告)日：2024-03-26

申请号：US17970080

申请日：2022-10-20

申请人： Mandos LLC

发明人： Bernardus Nicolaas Machielse ,  Allan Darling

IPC分类号： A61K31/724 ,  A61K9/00 ,  A61K9/08

CPC分类号： A61K31/724 ,  A61K9/0019 ,  A61K9/0085 ,  A61K9/08

摘要： This disclosure provides mixtures of beta-cyclodextrin molecules substituted at one or more hydroxyl positions by hydroxypropyl groups, the mixture optionally including unsubstituted beta-cyclodextrin molecules, for use as a pharmaceutically active ingredient; methods of making such mixtures; methods of qualifying such mixtures for use in a pharmaceutical composition suitable for intrathecal or intracerebroventricular administration; pharmaceutical compositions suitable for intrathecal or intracerebroventricular administration comprising such mixtures; and methods of using the pharmaceutical compositions for treatment of Niemann-Pick disease Type C.

公开(公告)号：US20240016829A1

公开(公告)日：2024-01-18

申请号：US18141832

申请日：2023-05-01

申请人： Mandos LLC

发明人： Bernardus Nicolaas Machielse ,  Allan Darling

IPC分类号： A61K31/724 ,  A61K9/00 ,  A61K9/08

CPC分类号： A61K31/724 ,  A61K9/08 ,  A61K9/0085 ,  A61K9/0019

摘要： This disclosure provides mixtures of beta-cyclodextrin molecules substituted at one or more hydroxyl positions by hydroxypropyl groups, the mixture optionally including unsubstituted beta-cyclodextrin molecules, for use as a pharmaceutically active ingredient; methods of making such mixtures; methods of qualifying such mixtures for use in a pharmaceutical composition suitable for intrathecal or intracerebroventricular administration; pharmaceutical compositions suitable for intrathecal or intracerebroventricular administration comprising such mixtures; and methods of using the pharmaceutical compositions for treatment of Niemann-Pick disease Type C.

公开(公告)号：US20230364175A1

公开(公告)日：2023-11-16

申请号：US18316182

申请日：2023-05-11

申请人： April Brader ,  Joel Snook ,  Yohann Samarasinghe ,  Samarth Aggarwal

发明人： April Brader ,  Joel Snook ,  Yohann Samarasinghe ,  Samarth Aggarwal

IPC分类号： A61K36/886 ,  A61K36/355 ,  A61K36/19 ,  A61K31/4045 ,  A61K31/724 ,  A61K9/00 ,  A61P11/02 ,  A61P29/00

CPC分类号： A61K36/886 ,  A61K36/355 ,  A61K36/19 ,  A61K31/4045 ,  A61K31/724 ,  A61K9/0043 ,  A61P11/02 ,  A61P29/00

摘要： An herbal composition including Lonicera Japonica and Andrographis Paniculata, a method of preparing the herbal composition, and a method of administering the herbal composition to a subject in need thereof is disclosed. The method of administering can include intranasal administration.

公开(公告)号：US20230346825A1

公开(公告)日：2023-11-02

申请号：US18029340

申请日：2021-09-29

申请人： CYCLOLAB CYCLODEXTRIN RESEARCH AND DEVELOPMENT LABORATORY LTD.

发明人： István Puskás ,  Abdula KURKAYEV

IPC分类号： A61K31/724 ,  A61P25/28

CPC分类号： A61K31/724 ,  A61P25/28

摘要： The present invention generally relates to use of single isomer chemically modified cyclodextrins, namely, S-(carboxyalkyl)-thio-cyclodextrin salts in medication used for the prevention or treatment of lysosomal storage diseases. More particularly, the present invention relates to isomer-pure, single isomer hexakis-S-(carboxyalkyl)-hexathio-alpha-cyclodextrin sodium salts, heptakis-S-(carboxyalkyl)-heptathio-beta-cyclodextrin sodium salts and octakis-S-(carboxyalkyl)-octathio-gamma-cyclodextrin sodium salts in medication used for the prevention or treatment of lysosomal storage diseases.